Movement Alert｜Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival

Market Focus06-01

On June 1, Akeso (09926.HK) surged 11.77% in regular trading, trading at HK$128.0/share, with trading volume of HK$1.142 billion.

On the news front, Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy demonstrated statistically significant overall survival superiority over tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer, based on the Phase III HARMONi-6 study results presented at the ASCO Plenary Session. The ivonescimab arm reduced the risk of death by 34%, with a two-year survival rate of 64.7% versus 48.6% for the control arm. The study enrolled 532 patients.

This marks the first time in 61 years that a Chinese first-in-class drug's Phase III results have been selected for the ASCO Plenary Session as a Late-Breaking Abstract, with simultaneous publication in The Lancet. Additionally, over 40 clinical research results across multiple tumor types were presented at the conference, including cadonilimab data in renal cell carcinoma showing a 51.4% objective response rate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137101798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137101798","market":"us","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival","media":"Market Focus","content":"<p><p>On June 1, Akeso (09926.HK) surged 11.77% in regular trading, trading at HK$128.0/share, with trading volume of HK$1.142 billion.</p><p>On the news front, Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy demonstrated statistically significant overall survival superiority over tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer, based on the Phase III HARMONi-6 study results presented at the ASCO Plenary Session. The ivonescimab arm reduced the risk of death by 34%, with a two-year survival rate of 64.7% versus 48.6% for the control arm. The study enrolled 532 patients.</p><p>This marks the first time in 61 years that a Chinese first-in-class drug's Phase III results have been selected for the ASCO Plenary Session as a Late-Breaking Abstract, with simultaneous publication in The Lancet. Additionally, over 40 clinical research results across multiple tumor types were presented at the conference, including cadonilimab data in renal cell carcinoma showing a 51.4% objective response rate.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 11.77% in Regular Trading, ASCO Plenary Session Data Shows Ivonescimab Beats PD-1 Combo in Overall Survival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, Akeso (09926.HK) surged 11.77% in regular trading, trading at HK$128.0/share, with trading volume of HK$1.142 billion.</p><p>On the news front, Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy demonstrated statistically significant overall survival superiority over tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer, based on the Phase III HARMONi-6 study results presented at the ASCO Plenary Session. The ivonescimab arm reduced the risk of death by 34%, with a two-year survival rate of 64.7% versus 48.6% for the control arm. The study enrolled 532 patients.</p><p>This marks the first time in 61 years that a Chinese first-in-class drug's Phase III results have been selected for the ASCO Plenary Session as a Late-Breaking Abstract, with simultaneous publication in The Lancet. Additionally, over 40 clinical research results across multiple tumor types were presented at the conference, including cadonilimab data in renal cell carcinoma showing a 51.4% objective response rate.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1137101798","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137101798","pubTimestamp":1780277597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, Akeso (09926.HK) surged 11.77% in regular trading, trading at HK$128.0/share, with trading volume of HK$1.142 billion.On the news front, Akeso's core product ivonescimab (PD-1/VEGF...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨11.77%，ASCO全会数据显示Ivonescimab总生存期击败PD-1 Combo","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 1, Akeso (09926.HK) surged 11.77% in regular trading, trading at HK$128.0/share, with trading volume of HK$1.142 billion.On the news front, Akeso's core product ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy demonstrated statistically significant overall survival superiority over tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer, based on the Phase III HARMONi-6 study results presented at the ASCO Plenary Session. The ivonescimab arm reduced the risk of death by 34%, with a two-year survival rate of 64.7% versus 48.6% for the control arm. The study enrolled 532 patients.This marks the first time in 61 years that a Chinese first-in-class drug's Phase III results have been selected for the ASCO Plenary Session as a Late-Breaking Abstract, with simultaneous publication in The Lancet. Additionally, over 40 clinical research results across multiple tumor types were presented at the conference, including cadonilimab data in renal cell carcinoma showing a 51.4% objective response rate.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137101798","isCrawlerRequest":true}